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Abstract
Introduction: The relationship between oesophageal radiation dose volume metrics and dysphagia in patients
having chemoradiation (CRT) for non-small cell lung cancer (NSCLC) is well established. There is also some evidence
that neutropenia is a factor contributing to the severity of oesophagitis. We retrospectively analysed acute radiation
oesophagitis (ARO) rates and severity in patients with NSCLC who received concurrent chemotherapy and high
dose radiation therapy (CRT). We investigated if there was an association between grade of ARO, neutropenia and
radiation dose volume metrics.
Material and methods: Patients with NSCLC having concurrent CRT who had RT dose and toxicity data available
were eligible. Exclusion criteria included previous thoracic RT, treatment interruptions and non-standard dose regimens.
RT dosimetrics included maximum and mean oesophageal dose, oesophagus dose volume and length data.
Results: Fifty four patients were eligible for analysis. 42 (78 %) patients received 60 Gy. Forty four (81 %)
patients received carboplatin based chemotherapy. Forty eight (89 %) patients experienced ARO ≥ grade 1
(95 % CI: 78 % to 95 %). ARO grade was associated with mean dose (rs = 0.27, p = 0.049), V20 (rs = 0.31,
p = 0.024) and whole oesophageal circumference receiving 20 Gy (rs = 0.32 p = 0.019). In patients who received these
doses, V20 (n = 51, rs = 0.36, p = 0.011), V35 (n = 43, rs = 0.34, p = 0.027) and V60 (n = 25, rs = 0.59, P = 0.002) were
associated with RO grade. Eleven of 25 (44 %) patients with ARO ≥ grade 2 also had ≥ grade 2 acute neutropenia
compared with 5 of 29 (17 %) patients with RO grade 0 or 1 (p = 0.035).
Conclusion: In addition to oesophageal dose-volume metrics, neutropenia may also be a risk factor for higher grades
of ARO.
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Introduction
Acute radiation oesophagitis (ARO) is a common tox-
icity associated with thoracic radiotherapy (RT) when
the treated volume includes the mediastinum. The inci-
dence and severity of the resulting dysphagia is related
to the dose and volume of oesophagus treated [1, 2]. In
patients receiving treatment for lung cancer with cura-
tive intent, the administration of concurrent chemother-
apy has been shown to improve survival compared with
sequential administration [3]. However, concurrent treat-
ment is also associated with increased oesophageal tox-
icity. This may be the result of a direct radiosensitising
effect of the chemotherapy, or it could be an indirect ef-
fect of chemotherapy induced neutropenia which results
in impaired healing of the oesophageal epithelium. In
support of this latter hypothesis, de Ruysscher et al.
observed a significant association between the maximal
grade of neutropenia and severity of ARO during che-
moradiotherapy (CRT) for NSCLC [4].
The primary aim of this retrospective analysis was to
assess the rates of acute oesophagitis in a cohort of
patients treated at our centre, with a particular focus on
dosimetric and haematologic risk factors, to independ-
ently verify the findings of de Ruysscher et al.
Materials and method
Approval was granted by the Peter MacCallum Cancer
Centre Institutional Ethics committee to conduct this
retrospective study. Criteria for inclusion of patient data
in the study included a pathological confirmation of
NSCLC and treatment with concurrent chemotherapy
and radical or high dose palliative radiotherapy at the
Peter MacCallum Cancer Centre (East Melbourne cam-
pus). Exclusion criteria included previous thoracic RT,
inconsistent radiation dose per fraction and hyper-
fractionated radiation schedules. We also excluded
patients with RT treatment interruptions ≥ 5 days, as mu-
cosal recovery during the break may have confounded in-
terpretation of the relationship between the oesophageal
dose volume metrics and grade of oesophagitis.
Patient characteristics, treatment and toxicity data were
extracted from paper and electronic medical records. Clin-
ical data included the use of nasogastric (NG) or percu-
taneous endoscopic gastrostomy (PEG) tube, systemic
steroids, proton pump inhibitors (PPI) and H2 receptor
antagonists prior to or during treatment. Patients’ weight
loss, smoking status, presence of auto-immune disease,
diabetes and/or reflux, and use of analgesia were recorded.
Treatment data included total radiation dose, dose per
fraction, overall treatment time and chemotherapy sched-
ules. The presence and grade of acute and late
oesophagitis, skin toxicity and neutropenia were assessed
in accordance with Common Toxicity Criteria for Adverse
Events (CTCAE v3.0). Acute toxicities were defined from
the first day of treatment to day 90 and late toxicities were
defined from day 91 after the start of RT. Toxicity assess-
ments were undertaken by a radiation oncologist at
weekly intervals and by a nurse at additional time-points.
During treatment neutropenia data were obtained from
pre-chemotherapy blood monitoring. The timing of treat-
ment reviews and blood tests varied between patients.
Three-dimensional conformal RT planning was per-
formed on Xio (Computerized Medical Systems CMS, St
Louis, MO, USA), using a fast superposition algorithm
and delivered with 6MV photons. Planning was per-
formed in accordance with ICRU guidelines, including
dose homogeneity within the planning target volume
(PTV) of +7 %/-5 % of the prescribed dose. The outer
muscular border of the oesophagus was delineated from
the cricoid (superior border) to the gastro-oesophageal
junction (inferior border) on CT derived images, using
soft-tissue window/level settings. Anatomical and dosi-
metric endpoints included the absolute length (cm) and
volume (cm3) of oesophagus, maximum (Dmax) and
mean (Dmean) oesophageal doses and percentage vol-
ume of oesophagus receiving 20 to 60 Gy (Vx, in 5 Gy
increments). The percentage length of oesophagus re-
ceiving 20 to 60 Gy (in 10 Gy increments) was recorded
for dose encompassing the whole oesophageal circum-
ference (LWO) and the partial oesophageal circumfer-
ence (LPO).
The rate of ARO was described as the percentage of
patients in the study who had experienced ARO of at
least grade 1. The rate of late oesophagitis and the rate
of high grade ARO (grade 3 or 4) were reported in the
same manner. All percentages of oesophagitis were re-
ported together with a 95 % confidence interval (95 %
CI) based on the binomial distribution. Assessment of
potential prognostic factors with respect to ARO was done
using Wilcoxon rank sum test and Spearman’s correlation.
ARO, acute neutropenia and acute skin reaction were
dichotomised as low grade (0 + 1) vs. high grade (2 + 3 +
4). The association of ARO with acute neutropenia and
acute skin reaction was examined using Barnard’s test. All
p-values are 2-sided without adjustment for multiplicity.
All statistical analyses were performed in R (R Develop-
ment Core Team (2012). R: A language and environment
for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
http://www.R-project.org/).
Results
Eighty four patients met the eligibility criteria for inclu-
sion in this study. The archived radiotherapy planning
data of 30 patients were irretrievable; therefore these pa-
tients were excluded from the analysis. Characteristics of
the remaining 54 patients are presented in Table 1.
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Table 2 shows the treatment details for CRT and any
prescribed other therapies including steroids and anal-
gesia. 42 (78 %) patients received CRT with a radical
dose of 60 Gy. The remaining 12 (22 %) patients re-
ceived high palliative doses ranging between 30 and
50 Gy, details of which have been published previously
[5]. No patient experienced a treatment break. The me-
dian change in weight from the start to the end of RT
was -1Kg, ranging from −8.5Kg to 3.5Kg.
The incidence and grade of acute and late oesophageal
toxicities are presented in Table 3. Of the 54 patients in-
cluded in the trial, 48 (89 %) had ARO of at least grade
1 (95 % CI: 78 % to 95 %) and 5 (9 %) patients had late
oesophagitis of at least grade 1 (95 % CI: 4 % to 20 %).
Of the 29 patients with ARO grade ≤ 1, 5 (17 %) experi-
enced high grade acute neutropenia (grade ≥ 2). In con-
trast, of the 25 patients with high grade ARO, 11 (44 %)
experienced high grade acute neutropenia (p = 0.035).
The maximum grade of oesophagitis was not signifi-
cantly associated with the maximum grade of acute skin
reaction (p = 0.529). There was not a statistically
Table 1 Patient characteristics and clinical factors
Variable Category Count %
Gender Female 14 25.9
Male 40 74.1










M Stage 0 46 85.2
1 5 9.3
X 3 5.6
Smoking Current smoker 9 16.7
Ex-smoker (<6 months) 10 18.5
Ex-smoker (> =6 months) 32 59.3
Never smoked 3 5.6
Autoimmune disease No 52 96.3
Yes 2 3.7
Diabetes No 46 85.2
Yes 8 14.8
Reflux oesophagitis No 42 77.8
Yes 12 22.2
Table 2 Treatment details
Variable Category Count %
RT dose received <60Gy 12 22.2
60Gy 42 77.8
RT type High dose palliative 10 18.5
Radical 44 81.5
RT breaks No 54 100
Yes 0 0
Chemo regimen Carboplatin + paclitaxel + gefitinib 4 7.4
Carboplatin + paclitaxel weekly 20 37
Carboplatin weekly 3 5.6
Carboplatin weeks 1 and 6 17 31.5
Gemcitabine weekly 8 14.8
Vinorelbine + Cisplatin weekly 2 3.7
Neoadjuvant chemo No 52 96.3
Yesa 2 3.7
NGPEG pre CRT No 54 100
Yes 0 0
NGPEG during CRT No 53 98.1
Yes 1 1.9
Steroids pretreatment No 49 90.7
Yes 5 9.3
Steroids during No 27 50
Yes 27 50
PPI pre No 45 83.3
Yes 9 16.7
PPI during No 34 63
Yes 20 37
H2Antag pre CRT No 52 96.3
Yes 2 3.7
H2Antag during CRT No 46 85.2
Yes 8 14.8
Local analgesia No 17 31.5
Yes 37 68.5
Type local analgesia Aluminium hydroxide and
oxethazaine (Mucaine)
12 32.4
Lignocaine viscous and Mucaine 22 59.5
Lignocaine viscous only 3 8.1
Systemic analgesia No 18 33.3
Yes 36 66.7
Type sys analgesia non-opioid 8 22.2
strong opioid 21 58.3
weak opioid 7 19.4
aOf the 2 patients who received neoadjuvant chemotherapy, 1 received
Carboplatin + Paclitaxel weekly and 1 received Carboplatin + Gemcitabine
NGPEG Nasogastric tube or PEG
PPI proton pump inhibitor
H2antag Histamine H2 receptor antagonist
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significant association between grade of ARO and sex
(p = 0.722) or dose, when dichotomised to <60 Gy
and 60 Gy (p = 0.401).
The mean (SD) oesophageal length was 22.4 cm (2.2)
and oesophageal volume was 86.9 cm3 (16.6). The mean
(SD) RT field length was 14.2 cm (3.9). Table 4 illustrates
details of the RT dosimetric data and the association of
oesophageal dose with ARO grade for all patients and
the subset of patients where the oesophagus received the
pre-specified dosimetric endpoint. For all patients, the
mean (SD) oesophageal Dmax was 50.2 Gy (18) and the
mean (SD) oesophageal Dmean was 20.8 Gy (10.8).
When analysing the association between ARO grade
and Vx parameters, there was a statistically significant
correlation between the grade of ARO and percentage of
oesophagus treated at 20 Gy for the whole patient
cohort (n = 54, rs = 0.306, p = 0.024) and the subset of
patients with oesophagus volumes treated to 20 Gy
(n = 51, rs = 0.355, p = 0.011). The correlation between
the grade of ARO and percentage of oesophagus
treated at 60 Gy was not statistically significant for
the whole cohort (n = 54, rs = 0.104, p = 0.455) but
highly significant for the subset of patients receiving
60 Gy to the oesophagus (n = 25, rs = 0.591, p = 0.002).
As shown in Table 4, the percentage of oesophagus
receiving at least 25 Gy (n = 50, rs = 0.303, p = 0.033),
35 Gy (n = 43, rs = 0.337, p = 0.027) were also statisti-
cally significant in the subset of patients receiving
25 Gy and 35 Gy to the oesophagus, respectively.
The analysis of association between ARO grade and
irradiated length showed a statistically significant correl-
ation in patients receiving 60 Gy to the partial
oesophageal circumference (n = 27, r = 0.428, p = 0.026)
but not in patients where the whole oesophageal circum-
ference was irradiated to 60 Gy (n = 6, r = 0.147, p =
0.781). For the whole patient cohort, only the whole
oesophageal circumference treated to 20 Gy was statisti-
cally significantly associated with acute oesophagitis
grade (r = 0.319, p = 0.019). Fig. 1 and Fig. 2 illustrate the
relationship of grade of acute oesophagitis with volume
and length receiving 20 Gy, respectively.
The relationship of neutropenia and oesophagitis was
assessed on all patients and also separately in the subsets
of patients with >50 % of oesophagus volume receiving
20Gy and ≤50 % of oesophagus volume receiving 20Gy
and the results presented in Table 5. Higher grades of
neutropenia were associated with higher grades of
oesophagitis when assessed in the whole cohort. Despite
not achieving statistical significance, the results from
both volume subsets were consistent with the result for
the whole cohort, probably a reflection of the small
number of patients in the subsets. If however the re-
lationship between oesophagitis and neutropenia is
tested adjusting for percentage of oesophagus volume
receiving 20Gy (as a continuous variable), neutropenia
was associated with oesophagitis (OR = 3.82 95 % CI
[1.06 – 15.79], p = 0.048).
Discussion
ARO is a common, painful and debilitating toxicity asso-
ciated with high dose CRT for locally advanced NSCLC,
and mitigation of the risk of high grade ARO should be
a priority of thoracic radiation oncology research.
Oesophageal dose and volume are well recognised risk
factors [1, 2], and our data are consistent with the litera-
ture in this regard. All of our patients received concur-
rent chemotherapy, also a recognised risk factor,
although it is not known whether as a result of direct
radiosensitisation of the oesophageal mucosa, or indir-
ectly through chemotherapy induced neutropenia, or a
combination of both. We have shown a significant asso-
ciation between grade of ARO and grade of neutropenia,
supporting the previous findings of de Ruysscher et al.
in favour of an indirect effect [4]. The implications are
that existing models predicting severity of ARO based
purely on oesophageal dose volume metrics [1] are over-
simplified and may need refinement by adjustment for
the effect of neutropenia.
It is not surprising that there should be a relationship
between grade of ARO and neutropenia. Chemotherapy
and RT are known to reduce the integrity of the
oesophageal mucosal epithelium, thereby damaging the
first line of defence against pathogens [6]. Healing of the
Table 3 Description of toxicities
Variable Category Count % [95 % CI]
Grade of acute
oesophagitis
0 6 11.1 [5.2 - 22.2]
1 23 42.6 [30.3 - 55.8]
2 17 31.5 [20.7 - 44.7]
3 8 14.8 [7.7 - 26.6]
Late oesophagitis
recorded
No 25 46.3 [33.7 - 59.4]
Yes 29 53.7 [40.6 - 66.3]
Grade of late
oesophagitis
0 24 82.8 [65.5 - 92.4]
1 2 6.9 [1.9 - 22.0]
2 3 10.3 [3.6 - 26.4]
Reason no late
oesophagitis
Disease progression 6 25.0 [12.0 - 44.9]
New second primary 1 4.2 [0.2 - 20.2]
Not documented in
clinical record
9 37.5 [21.2 - 57.3]
Patient died before
first assessment
3 12.5 [4.3 - 31.0]
Patient had surgery 1 4.2 [0.2 - 20.2]
Patient lost to F/U 4 16.7 [6.7 - 35.9]
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Table 4 Radiation therapy dosimetric data and the relationship of oesophageal dose with grade of acute oesophagitis
All patients (n = 54) Only patients receiving pre-specified dose to the oesophagus
Variable Mean sd Spearman correlation p-value n Spearman correlation p-value
Dmax (Gy) 50.2 18.0 0.143 0.302 - - -
Dmean (Gy) 20.8 10.8 0.269 0.049 - - -
VO20 43.9 23.1 0.306 0.024 51 0.355 0.011
VO25 40.8 22.1 0.297 0.029 50 0.303 0.033
VO30 34.8 23 0.238 0.083 49 0.269 0.062
VO35 30.8 24.4 0.201 0.146 43 0.337 0.027
VO40 26.9 23.9 0.162 0.243 41 0.302 0.055
VO45 23.8 23 0.163 0.24 38 0.310 0.058
VO50 21.1 21.1 0.152 0.273 38 0.289 0.078
VO55 17.1 19.1 0.124 0.371 37 0.290 0.081
VO60 6.9 10.9 0.104 0.455 25 0.591 0.002
LPO20 48.9 21 0.205 0.136 51 0.240 0.090
LPO30 42.2 21.4 0.134 0.336 50 0.107 0.458
LPO40 34.2 24.7 0.106 0.448 41 0.206 0.196
LPO50 29.9 24 0.101 0.469 38 0.189 0.255
LPO60 12.5 16.1 0.048 0.728 27 0.428 0.026
LWO20 29.8 22.7 0.319 0.019 43 0.185 0.236
LWO30 20.5 20.4 0.250 0.068 36 0.148 0.389
LWO40 14.4 18.6 0.231 0.093 30 0.248 0.186
LWO50 8.6 14.1 0.210 0.128 20 0.214 0.364
LWO60 1 3.8 0.139 0.316 6 0.147 0.781
VOx Percentage volume of oesophagus receiving x dose (%), LPOx Percentage length of partial oesophagus receiving x dose (%), LWOx Percentage length of
whole oesophagus receiving x dose (%). Values in bold type indicate statistical significance, p < 0.05
Fig. 1 Box-and-whisker plot showing the percentage of oesophagus
volume treated at 20Gy according to grade of acute oesophagitis
Fig. 2 Box-and-whisker plot showing the percentage of oesophagus
length treated at 20Gy (whole circumference) according to grade of
acute oesophagitis
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mucosa will be delayed if the inflammatory response is
impaired due to a lack of neutrophils. Indeed, prophylac-
tic G-CSF has been investigated for its ability to reduce
mucositis in patients having radiotherapy for head and
neck cancer. In one randomised trial, G-CSF was associ-
ated with a non-significant reduction in mucositis, but
also a reduction in local cancer control [7].
In de Ruysscher’s study, neutropenia was only ob-
served in patients who received CRT and it was the most
significant parameter for predicting ARO [4]. Although
our patient numbers were limited, they are consistent
with the findings of de Ruysscher et al. and we are not
aware of any other reports implicating neutropenia as a
contributory factor to the grade of ARO.
Several dosimetric endpoints in our study were statisti-
cally associated with ARO. These included the mean
oesophageal dose (p = 0.049), consistent with some pre-
vious studies [1]. Low doses to large oesophageal vol-
umes were statistically significantly associated with high
oesophageal toxicity in our cohort of patients receiving
CRT, including the volume receiving 20Gy (p = 0.026)
and whole oesophageal circumference receiving 20Gy
(p = 0.019). In the subset analysis of patients treated
to given doses, the oesophagus V60 was also associated
with oesophagitis (rs = 0.591, p = 0.002). Although this
finding represents a small subset of 25 patients, it is con-
sistent with other literature, including Bradley et al., who
reported the association between oesophagitis and V60 in
a study of 166 patients [8]. Similar to our own find-
ings, Takeda et al. [9] and Belderbos et al. [10] con-
cluded that the most significant dosimetric parameter
was the volume of oesophagus receiving at least 35Gy
(p < 0.001). These data were based on the incidence
of ≥Grade 2 oesophagitis, whereas our own data are
for ≥Grade 1 toxicity.
The proximity of primary lung cancers and medias-
tinal nodes to the oesophagus in many CRT candidates
means that inclusion of the oesophagus within the
treated volume is often unavoidable, even with IMRT
techniques. The opportunities for reducing oesophageal
dose and volume are therefore limited. Our results
suggest that an alternative strategy worth investigating
may be the use of concurrent chemotherapy regimens
which are less likely to cause myelosuppression but
without loss of therapeutic benefit.
Conclusions
This study suggests that in patients receiving concurrent
chemoradiotherapy for NSCLC risk factors for radiation
oesophagitis include not only oesophageal dose and vol-
ume, but also neutropenia. The determination of
oesophageal dose volume constraints may not be reliable
unless this is taken into account. It may be possible to
reduce the risk of high grade oesophagitis by choosing a
concurrent chemoradiotherapy regimen with a low like-
lihood of myelosuppression.
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